Discovery of a Highly Potent and Selective Degrader Targeting Hematopoietic Prostaglandin D Synthase via In Silico Design.
Animals
Humans
Male
Mice
Bone Marrow
/ enzymology
Cardiomegaly
/ metabolism
Cell Line, Tumor
Computer Simulation
Drug Discovery
Enzyme Inhibitors
/ chemistry
Intramolecular Oxidoreductases
/ antagonists & inhibitors
Ligands
Lipocalins
/ antagonists & inhibitors
Mice, Inbred mdx
Molecular Docking Simulation
Muscular Dystrophy, Duchenne
/ genetics
Proteolysis
Journal
Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531
Informations de publication
Date de publication:
11 11 2021
11 11 2021
Historique:
pubmed:
16
10
2021
medline:
1
2
2022
entrez:
15
10
2021
Statut:
ppublish
Résumé
Targeted protein degradation by proteolysis-targeting chimera (PROTAC) is one of the exciting modalities for drug discovery and biological discovery. It is important to select an appropriate linker, an E3 ligase ligand, and a target protein ligand in the development; however, it is necessary to synthesize a large number of PROTACs through trial and error. Herein, using a docking simulation of the ternary complex of a hematopoietic prostaglandin D synthase (H-PGDS) degrader, H-PGDS, and cereblon, we have succeeded in developing
Identifiants
pubmed: 34652145
doi: 10.1021/acs.jmedchem.1c01206
doi:
Substances chimiques
Enzyme Inhibitors
0
Intramolecular Oxidoreductases
EC 5.3.-
Ligands
0
Lipocalins
0
prostaglandin R2 D-isomerase
EC 5.3.99.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM